98%
921
2 minutes
20
Purpose: Pituitary adenomas are much rarer in children than in adults. We aimed to analyze their imaging characteristics in this age group and to compare them according to the hormonal secretion. We conducted an observational monocentric retrospective study on clinical and imaging data.
Methods: We analyzed imaging features before surgery or drug treatment of pituitary adenomas in children confirmed by histopathology or hormonal secretion. We assessed tumoral signal intensity, volume and aggressiveness, and compared it according to the hormonal secretion.
Results: We included 31 children (13 lactotroph (42%), 8 corticotroph (26%), 5 somatotroph (16%), 5 plurihormonal adenomas (16%) including 1 non-secreting macroadenoma) with a median age of 13 years (range 2-16 years-old), without age or sex difference between secretion types. Lactotroph and somatotroph adenomas were larger than corticotroph adenomas (p = 0.007) and were more aggressive (p = 0.01). They also had higher signal intensity on T2-weighted images (p = 0.04). T1 signal intensity was similar between the groups on pre and post-contrast images (lower enhancement than the normal pituitary). No non-secreting micro-adenoma became clinically significant enough to lead to a pathological confirmation or specific treatment. Genetic research was conducted on 20 children, finding MEN1 mutations in 80% of the patients.
Conclusions: Pituitary adenomas in children are rare but should be considered when facing similar imaging features than in adults. Imaging characteristics may allow to suspect the hormonal secretion.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00062-025-01499-3 | DOI Listing |
Endocr Connect
September 2025
Centre for Higher Education Development, University of Cape Town.
Background: Cortisol and growth hormone are important for sleep regulation and cognition. Sleep is critical for cognitive functioning, and memory consolidation. Patients with pituitary disease experience hormonal dysregulation, impaired sleep quality, and cognitive dysfunction.
View Article and Find Full Text PDFJ Clin Endocrinol Metab
September 2025
Endocrinology & Nutrition Department, Hospital Universitario de Vall d´Hebron, Barcelona, Spain.
Objective: Pituitary adenomas (PAs) are one of the three major lesions in Multiple Endocrine Neoplasia type 1 (MEN1), with a prevalence of 32 to 58%, yet their specific risk factors remain unidentified. This study aimed to identify predictors influencing PA occurrence in MEN1.
Methods: This nationwide, multicenter, retrospective cohort study involved 240 MEN1 patients, 55.
Pituitary
September 2025
Facoltà Di Medicina E Chirurgia, Università Cattolica del Sacro Cuore, Rome, Italy.
Introduction: Pituitary adenomas (PAs) are generally benign neoplasms, though in rare cases may exhibit aggressive behavior. In 2024, the PANOMEN-3 workshop released a new clinical-pathological classification. The objective of this study was to examine the potential of the PANOMEN-3 classification to predict prognosis of PAs and guide treatment in our single center cohort of patients with PAs.
View Article and Find Full Text PDFClin Chim Acta
September 2025
Pain Management Center, Hospital Angeles Mocel, Mexico City, Mexico.
Glucose metabolism alterations are frequently observed in patients with secretory pituitary adenomas. The most commonly secreted hormones in these tumors include prolactin, growth hormone (GH), adrenocorticotropic hormone (ACTH), and thyroid-stimulating hormone (TSH), all of which can disrupt glucose homeostasis through distinct pathophysiological mechanisms. Prolactin stimulates pancreatic β-cell proliferation, enhances insulin gene transcription, increases intracellular insulin content, and augments glucose-induced insulin secretion.
View Article and Find Full Text PDFGenet Test Mol Biomarkers
September 2025
Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Male patients with prolactinomas exhibit greater invasiveness, resistance to dopamine agonists, making treatment more challenging. This study aims to explore the potential different genes contributing to sex disparities in prolactinomas. Weighted gene co-expression network analysis and differential expressed genes analysis were performed to identify sex-related hub genes.
View Article and Find Full Text PDF